| Name | Title | Contact Details |
|---|
Viracta is focused on advancing a proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr Virus, and will pursue opportunities to address other serious virus-associated disease.
We founded Cedilla at a time of fundamental and rapidly growing insight into the mechanisms underlying protein stability. Small molecules that degrade or stablize target proteins are precedented, but have been discovered serendipitously. Cedilla is taking an integrated approach to discover new drugs with this mode of action. Our present focus is to develop novel medicines in oncology, but this approach will also be applicable to other fields, including central nervous system disorders and genetic diseases. Cedilla launched with $56.2 million in Series A funding from Third Rock Ventures.
Bradmer Pharmaceuticals Inc. is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Evolution Medical Communications, LLC is a Philadelphia, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Alberta Conservation Association is a Edmonton, AB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.